SeaStar_SM_LogoCard.png
FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis
06 nov. 2024 09h00 HE | SeaStar Medical Holding Corporation
This represents the fourth indication granted a Breakthrough Device Designation for the SCD by FDA DENVER, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...
SeaStar_SM_LogoCard.png
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial
01 nov. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial
23 oct. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Oct. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers
22 oct. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis
18 oct. 2024 08h30 HE | SeaStar Medical Holding Corporation
The pace of patient enrollment has significantly accelerated following a summertime slowdown DENVER, Oct. 18, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...
SeaStar_SM_LogoCard.png
SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week
15 oct. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit
09 oct. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Oct. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
08 oct. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial
25 sept. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
James (Josh) Wilson Faruqi & Faruqi, LLP
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SeaStar
29 août 2024 19h12 HE | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options If...